In a nutshell This study aimed to compare outcomes of fludarabine–treosulfan (FT), thiotepa–busulfan–fludarabine (TBF), and fludarabine, Ara-C, amsacrine, total body irradiation/busulfan, cyclophosphamide (FLAMSA) in the treatment of patients with relapsed or unresponsive acute myeloid leukemia (AML). The study found that all...
Read MoreCurrent treatment status-Undergoing active treatment-Partial response Posts on Medivizor
Evaluating isatuximab plus pomalidomide and dexamethasone for non-responsive multiple myeloma
In a nutshell This study evaluated isatuximab, pomalidomide (Imnovid) and dexamethasone (Decadron) for recurrent or non-responsive multiple myeloma (MM). This study concluded that this treatment combination was safe and effective for these patients. Some background There are several treatment options for patients with MM. Most initial...
Read MoreEvaluating rituximab plus lenalidomide for recurrent or non-responsive indolent non-Hodgkin lymphoma
In a nutshell This study evaluated the safety and effectiveness of rituximab (Rituxan) plus lenalidomide (Revlimid) for patients with recurrent or non-responsive non-Hodgkin’s lymphoma (NHL). This study concluded that lenalidomide was well-tolerated and improved the effectiveness of rituximab in these patients. Some background Follicular...
Read MoreEvaluating long-term outcomes after radiation and stem cell transplantation for recurrent or unresponsive Hodgkin lymphoma
In a nutshell This study evaluated the long-term outcomes of patients with recurrent or non-responsive classical Hodgkin’s lymphoma (cHL) after undergoing radiation, chemotherapy, and autologous stem cell transplantation (autoSCT). This study concluded that total lymphoid irradiation (TLI) therapy before a bone marrow transplant can improve...
Read MoreEvaluating PD-1 inhibitors for patients with Hodgkin lymphoma in a real-world setting
In a nutshell This study evaluated the safety and effectiveness of PD-1 inhibitors for patients with classical Hodgkin lymphoma (cHL) outside of clinical trials. This study concluded that PD-1 inhibitors are safe and effective for these patients. Some background Standard first-line chemotherapy is highly effective in treating 70 – 80% of...
Read MoreThe impact of graft-versus-lymphoma effect on outcomes after reduced intensity conditioned stem cell transplant
In a nutshell This study aimed to investigate the impact of the graft-versus-lymphoma effect on the outcomes for patients with lymphoma who are treated with reduced-intensity conditioning (RIC) with alemtuzumab (Lemtrada) allogeneic hematopoietic stem cell transplant (allo-HSCT). This study concluded that the graft-versus-lymphoma effect leads...
Read MoreThe impact of graft-versus-lymphoma effect on outcomes after reduced intensity conditioned stem cell transplant
In a nutshell This study aimed to investigate the impact of the graft-versus-lymphoma effect on the outcomes for patients with lymphoma who are treated with reduced-intensity conditioning (RIC) with alemtuzumab (Lemtrada) allogeneic hematopoietic stem cell transplant (allo-HSCT). This study concluded that the graft-versus-lymphoma effect leads to...
Read MoreIs nivolumab an effective treatment for relapsed and unresponsive Hodgkin lymphoma?
In a nutshell This study examined if nivolumab is an effective treatment for relapsed and unresponsive Hodgkin lymphoma. This study concluded that nivolumab is an effective treatment for these patients, regardless of previous stem cell treatment status. Some background Standard treatment for patients with Hodgkin lymphoma (HL) which has relapsed or...
Read MoreEvaluating carfilzomib plus dexamethasone for relapsed or refractory multiple myeloma
In a nutshell This study evaluated the impact of carfilzomib (Kyprolis) and dexamethasone (Decadron) on quality of life for patients with relapsed or refractory (does not respond to treatment) multiple myeloma (MM). This study concluded that patients treated with this combination had a higher quality of life. Some background MM is a...
Read MoreEvaluating ibrutinib plus nivolumab for relapsed or refractory CLL
In a nutshell This study evaluated the safety and effectiveness of ibrutinib (Imbruvica) plus nivolumab (Opdivo) for relapsed or unresponsive chronic lymphocytic leukemia (CLL). This study concluded that this treatment was well-tolerated and showed promising effectiveness in these patients. Some background Treatment remains challenging for...
Read MoreRituximab to treat unresponsive chronic lymphocytic leukemia in a real-world setting
In a nutshell This study examined the safety and effectiveness of rituximab (Rituxan) to treat relapsed or unresponsive chronic lymphocytic leukemia (CLL) in a real-world setting. Authors concluded that rituximab was safe and effective in these patients. Some background Chronic lymphocytic leukemia is a cancer of the immune system. It...
Read MoreComparing ibrutinib and ofatumumab in patients with previously treated chronic lymphocytic leukemia
In a nutshell This study aimed to investigate patient well-being and patient-reported outcomes in previously treated patients with chronic lymphocytic leukemia who receive ibrutinib (Imbruvica) or ofatumumab (Arzerra). They concluded that ibrutinib can improve quality of life while prolonging survival in these patients. Some background...
Read More
